Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23422751&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass Lee GM; Welsby IJ; Phillips-Bute B; Ortel TL; Arepally GMBlood 2013[Apr]; 121 (15): 2828-35Protamine is routinely used to reverse heparin anticoagulation during cardiopulmonary bypass (CPB). Heparin interacts with protamine to form ultralarge complexes that are immunogenic in mice. We hypothesized that patients exposed to protamine and heparin during CPB will develop antibodies (Abs) to protamine/heparin (PRT/H) complexes that are capable of platelet activation. Specimens from a recently completed prospective clinical trial (HIT [for heparin-induced thrombocytopenia] 5801 study; n = 500) of CPB patients were examined for PRT/H Abs at baseline, at time of hospital discharge (between days 3 through 7), and 30 days after CPB. PRT/H antibody features were characterized and correlated with adverse cardiovascular outcomes. We found a high incidence of PRT/H antibody formation (29%) in patients undergoing cardiac surgery. PRT/H Abs were of high titer (mean titer 1:14,744), showed heparin-dependent binding, and activated platelets in the presence of protamine. PRT/H Abs showed no cross-reactivity to platelet factor 4/heparin complexes, but were cross-reactive with protamine-containing insulin preparations. In the absence of circulating antigen at day 30, there were no complications of thrombocytopenia, thrombotic events, or long-term cardiovascular events. These studies show that Abs to PRT/H occur commonly after cardiac bypass surgery, share a number of serologic features with HIT Abs, including platelet activation, and may pose health risks to patients requiring drug reexposure.|*Cardiopulmonary Bypass[MESH]|Aged[MESH]|Antibodies/*blood[MESH]|Anticoagulants/administration & dosage/adverse effects/immunology[MESH]|Cross Reactions/immunology[MESH]|Enzyme-Linked Immunosorbent Assay[MESH]|Female[MESH]|Heparin Antagonists/administration & dosage/immunology[MESH]|Heparin/administration & dosage/adverse effects/*immunology[MESH]|Humans[MESH]|Incidence[MESH]|Insulin, Isophane/immunology[MESH]|Logistic Models[MESH]|Male[MESH]|Middle Aged[MESH]|Multivariate Analysis[MESH]|Outcome Assessment, Health Care[MESH]|Platelet Factor 4/immunology[MESH]|Protamines/administration & dosage/*immunology[MESH]|Protein Binding/immunology[MESH]|Thrombocytopenia/chemically induced/epidemiology/immunology[MESH]|Time Factors[MESH] |
